首页> 外文期刊>Research journal of engineering and technology >Kinetic Study of Granzyme B in Patients with Chronic Hepatitis Type B
【24h】

Kinetic Study of Granzyme B in Patients with Chronic Hepatitis Type B

机译:慢性乙型肝炎患者颗粒酶B的动力学研究

获取原文
获取原文并翻译 | 示例
           

摘要

Chronic hepatitis B (CHB) virus infection is affecting more than 350 million people worldwide, and can predispose for serious complications like liver cirrhosis and hepatocarcinoma. The development of CHB from active stage is the direct result of debilitated immune system which mainly depends on cytotoxic T- lymphocyte (CTL) and natural killer (NK) cells for controlling viral replication. These cells eliminate their targets through the secretion of two proteins: perforin and granzymes (Gzms). Thus, this study aimed to evaluate the activity and concentration of GzmB in patients with CHB. A total of 60 patients (30 newly diagnosed and 30 treated) were recruited for this case-control study. Other 30 age- and gender-matched apparently healthy subjected (negative for HBsAg) were involved as controls. Granzyme B kinetics and concentration were measured using ready commercial kits. Treated patients had significantly higher values of Km (8.57±0.796 × 10~(-5) M), than either untreated patients (7.17±0.69 × 10~(-5) M) or controls (7.24±0.82 × 10~(-5) M), while treated patients showed significantly lower values for Kcat and Kcat/Km (3.77±0.39 s~(-1) and 4.55×0.89 × 10~4 M~(-1). s~(-1) respectively) than either untreated patients (4.37±0.31 s~(-1) and 6.18±0.98 × 10~4 M~(-1). s~(-1) respectively) or controls (4.34±0.37 s~(-1) and 6.187±1.167 × 10~4 M~(-1). s~(-1) respectively). Mean GzmB concentration in control was 104.4±26.37 Pg/mL which significantly higher than that of untreated patients (44.3±8.73. Pg/mL which did not differ significantly from treated patients (42.33±9.09 Pg/mL). These data indicate the reduction in GzmB concentration in CHB which may reflect a defect in the production of this enzyme that predispose un individual to the chronic infection.
机译:慢性乙型肝炎(CHB)病毒感染正在影响全球超过3.5亿人,并且容易诱发严重的并发症,例如肝硬化和肝癌。 CHB从活跃期的发展是免疫系统衰弱的直接结果,免疫系统主要依赖于细胞毒性T淋巴细胞(CTL)和自然杀伤(NK)细胞来控制病毒复制。这些细胞通过分泌两种蛋白(穿孔素和粒酶(Gzms))消除了它们的靶标。因此,本研究旨在评估CHB患者中GzmB的活性和浓度。该病例对照研究共招募了60名患者(30名新诊断和30名接受治疗)。以其他30名年龄和性别相匹配的显然健康的受试者(HBsAg阴性)作为对照。使用现成的商业试剂盒测量颗粒酶B的动力学和浓度。与未治疗的患者(7.17±0.69×10〜(-5)M)或对照组(7.24±0.82×10〜(-)-相比,治疗的患者的Km值(8.57±0.796×10〜(-5)M)明显更高。 5)M),而接受治疗的患者的Kcat和Kcat / Km值分别显着较低(3.77±0.39 s〜(-1)和4.55×0.89×10〜4 M〜(-1)。s〜(-1)。 )或未治疗的患者(4.37±0.31 s〜(-1)和6.18±0.98×10〜4 M〜(-1).s〜(-1))或对照组(4.34±0.37 s〜(-1)和6.187±1.167×10〜4 M〜(-1)。s〜(-1))。对照的平均GzmB浓度为104.4±26.37 Pg / mL,明显高于未治疗的患者(44.3±8.73。Pg / mL,与治疗的患者无明显差异(42.33±9.09 Pg / mL)。 CHB中GzmB的浓度可能反映了这种酶的产生缺陷,使个体不易患慢性感染。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号